ABSTRACT
Background@#Postoperative pain following total knee arthroplasty (TKA) may hamper patients from a rapid recovery and increase perioperative blood loss and stress on the cardiovascular system. Therefore, our objective was to assess perioperative outcomes after TKA in patients who were not candidates for the additional nonsteroidal anti-inflammatory drugs (NSAIDs) in a multimodal pain control regimen. @*Methods@#Propensity score matching for age, sex, body mass index, American Society of Anesthesiologists class, and preoperative hemoglobin level was conducted on patients undergoing unilateral TKA, and thereby 52 patients remained in each group. The control group comprised patients who received parenteral parecoxib every 12 hours during the first 48 hours after TKA. The NoNSAIDs group did not receive NSAIDs because of known contraindications. Identical postoperative pain control including intravenous patient-controlled analgesia was applied for all patients. Visual analog scale (VAS) score for pain, knee flexion, blood loss, serum cardiac troponin-T (cTnT), and length of stay (LOS) were determined. @*Results@#The No-NSAIDs group had significantly higher VAS scores in 6–96 hours and consumed more morphine at 24 hours and 48 hours after the surgery than the control group. The No-NSAIDs group had significantly less knee flexion at 48 hours (p = 0.045) and tended to have more emesis and longer LOS than the control group. The blood loss of the No-NSAIDs and control group was 552.52 mL and 397.65 mL (p = 0.02), respectively, and blood transfusion rate was 23.1% and 17.3% (p = 0.63), respectively. The cTnT of the No-NSAIDs group rose over the first 48 hours and was significantly higher than that of the control group at 48 hours. @*Conclusions@#Patients who were not candidates for NSAIDs had significantly higher pain scores and consumed more morphine after TKA. They also tended to have greater blood loss and the rising of cardiac biomarkers during the first 48 hours after TKA.Hence, these patients may benefit from supplementary analgesia and appropriate perioperative monitoring.
ABSTRACT
Background@#Postoperative pain following total knee arthroplasty (TKA) may hamper patients from a rapid recovery and increase perioperative blood loss and stress on the cardiovascular system. Therefore, our objective was to assess perioperative outcomes after TKA in patients who were not candidates for the additional nonsteroidal anti-inflammatory drugs (NSAIDs) in a multimodal pain control regimen. @*Methods@#Propensity score matching for age, sex, body mass index, American Society of Anesthesiologists class, and preoperative hemoglobin level was conducted on patients undergoing unilateral TKA, and thereby 52 patients remained in each group. The control group comprised patients who received parenteral parecoxib every 12 hours during the first 48 hours after TKA. The NoNSAIDs group did not receive NSAIDs because of known contraindications. Identical postoperative pain control including intravenous patient-controlled analgesia was applied for all patients. Visual analog scale (VAS) score for pain, knee flexion, blood loss, serum cardiac troponin-T (cTnT), and length of stay (LOS) were determined. @*Results@#The No-NSAIDs group had significantly higher VAS scores in 6–96 hours and consumed more morphine at 24 hours and 48 hours after the surgery than the control group. The No-NSAIDs group had significantly less knee flexion at 48 hours (p = 0.045) and tended to have more emesis and longer LOS than the control group. The blood loss of the No-NSAIDs and control group was 552.52 mL and 397.65 mL (p = 0.02), respectively, and blood transfusion rate was 23.1% and 17.3% (p = 0.63), respectively. The cTnT of the No-NSAIDs group rose over the first 48 hours and was significantly higher than that of the control group at 48 hours. @*Conclusions@#Patients who were not candidates for NSAIDs had significantly higher pain scores and consumed more morphine after TKA. They also tended to have greater blood loss and the rising of cardiac biomarkers during the first 48 hours after TKA.Hence, these patients may benefit from supplementary analgesia and appropriate perioperative monitoring.
ABSTRACT
BACKGROUND: Various pre- and perioperative risk factors have been reported in association with blood loss in knee arthroplasty. However, the effect of the uncovered cancellous surface on blood loss in simultaneous bilateral total knee arthroplasty (SBTKA) by different prosthetic designs is not well elucidated. Therefore, this study aimed to compare the blood loss and transfusion rate between different knee prostheses in SBTKA and to identify risk factors that influence blood loss and transfusion after SBTKA. METHODS: Demographic and perioperative data of patients who underwent SBTKA using either a closed-box or an open-box femoral component of posterior-stabilized fixed-bearing (PS FB) knee system were retrospectively reviewed. The calculated blood loss (CBL) and blood transfusion rate were compared by using Student t-test and confirmed with multivariate regression analysis. RESULTS: There was no significant difference in preoperative parameters between 54 closed-box and 56 open-box PS FB TKAs. The CBL of the closed-box TKA group was 135.23 mL less (95% confidence interval [CI], −215.30 to −55.16; p = 0.001) than that of the open-box TKA group. However, the blood transfusion rates of the closed- and open-box TKA groups were not significantly different (24.1% and 38.5%, p = 0.11). For each additional minute of total operative time, 3.75 mL (95% CI, 1.75 to 5.76; p < 0.001) of blood loss was anticipated. For each additional mg/dL of preoperative hemoglobin, 71% (p < 0.001) reduction of blood transfusion probability was predicted. CONCLUSIONS: The use of closed- and open-box knee prostheses resulted in a significant difference in blood loss in SBTKA. Prolonged operative time also significantly increased CBL. Therefore, strategies to control the bleeding surface and shorten operative duration may be considered if blood loss is of special concern. The preoperative hemoglobin was the only factor that affects the probability of blood transfusion in SBTKA.
Subject(s)
Humans , Arthroplasty , Arthroplasty, Replacement, Knee , Blood Transfusion , Hemorrhage , Knee , Knee Prosthesis , Operative Time , Prostheses and Implants , Prosthesis Design , Retrospective Studies , Risk FactorsABSTRACT
Background: Proteinuria is a major predictor for renal progression in IgA nephropathy (IgAN). Thiazolidinediones were demonstrated to reduce proteinuria in patients with diabetic nephropathy.Objective: To investigate the effect of pioglitazone (PGZ) in proteinuric IgAN using randomized, double-blinded approach.Methods: Forty-one biopsy-proven IgAN patients with proteinuria (≥ 0.5g/day) who were currently treated with renin angiotensin system inhibitors and had at least two out of four risk factors for progressive disease (male gender, blood pressure \>150/90 mmHg, creatinine clearance of 20-80 mL/min/1.73m², and chronicity index \> 1) were randomly assigned to receive either PGZ 30 mg/day (PGZ group; n=21) or placebo (control group, n=20) for 16 weeks.Results: Baseline characteristics of patients in both groups were comparable. Following 16-week treatment, proteinuria in the PGZ group was significantly lower than the control group, [1.2 vs. 2.1 g/day (p \< 0.05)]. Patients in the PGZ group also showed a significant reduction in urinary excretion of TGF-β (from 361.4 to 234.4 ng/gCr) and VEGF (from 1353.1 to 765.1 ng/gCr) after 16-week treatment (p \< 0.05, both).Conclusion: PGZ significantly reduced proteinuria, urinary TGF-β, and urinary VEGF in IgAN patients. These findings suggest that PGZ could have a role in the treatment of proteinuric IgAN. Further studies with larger cases and longer follow-up time are warranted.